$PIRS
Pieris Pharmaceuticals Inc Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000158364820000015 Filed on March 13, 2020

Income Statement

Concept	2020 Q1	2019 Q1	2018 Q4
Revenue	$13.26M	$8.545M	$4.910M
YoY Change	55.19%	105.8%	-72.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.360M	$4.930M	$4.560M
YoY Change	-11.56%	13.33%	-28.64%
% of Gross Profit
Research & Development	$12.76M	$14.30M	$13.00M
YoY Change	-10.76%	80.14%	146.68%
% of Gross Profit
Depreciation & Amortization	$339.0K	$166.0K	$160.0K
YoY Change	104.22%	23.88%	60.0%
% of Gross Profit
Operating Expenses	$17.12M	$19.23M	$17.56M
YoY Change	-10.98%	56.48%	50.6%
Operating Profit	-$3.856M	-$10.68M
YoY Change	-63.91%	31.31%
Interest Expense	$319.0K	$506.0K	$470.0K
YoY Change	-36.96%	55.69%	213.33%
% of Operating Profit
Other Income/Expense, Net	-$60.00K	-$171.0K	$330.0K
YoY Change	-64.91%	-81.06%	-66.67%
Pretax Income	-$3.600M	-$10.35M	-$11.85M
YoY Change	-65.21%	18.75%	-255.31%
Income Tax		$0.00	-$160.0K
% Of Pretax Income
Net Earnings	-$3.600M	-$10.35M	-$11.68M
YoY Change	-65.21%	18.75%	-255.94%
Net Earnings / Revenue	-27.15%	-121.1%	-237.88%
Basic Earnings Per Share
Diluted Earnings Per Share	-$65.21K	-$203.5K	-$215.7K
COMMON SHARES
Basic Shares Outstanding	55.21M shares	49.15M shares	54.15M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$86.80M	$110.8M	$128.1M
YoY Change	-21.66%	-30.58%	76.45%
Cash & Equivalents	$47.43M	$52.09M	$74.87M
Short-Term Investments	$39.30M	$58.70M	$53.20M
Other Short-Term Assets	$4.300M	$6.400M	$4.600M
YoY Change	-32.81%	100.0%	187.5%
Inventory
Prepaid Expenses
Receivables	$7.267M	$7.128M	$2.701M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$98.37M	$124.3M	$135.4M
YoY Change	-20.85%	-25.17%	50.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.34M	$4.893M	$5.049M
YoY Change	315.78%	10.08%	25.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$1.887M	$2.030M	$910.0K
YoY Change	-7.04%	1461.54%	600.0%
Total Long-Term Assets	$25.40M	$18.89M	$5.959M
YoY Change	34.46%	163.91%	-57.7%
TOTAL ASSETS
Total Short-Term Assets	$98.37M	$124.3M	$135.4M
Total Long-Term Assets	$25.40M	$18.89M	$5.959M
Total Assets	$123.8M	$143.2M	$141.3M
YoY Change	-13.55%	-17.35%	36.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.500M	$3.728M	$3.350M
YoY Change	-6.12%	92.76%	36.62%
Accrued Expenses	$6.939M	$9.216M	$9.114M
YoY Change	-24.71%	40.1%	47.71%
Deferred Revenue	$10.04M	$28.18M	$35.61M
YoY Change	-64.36%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.48M	$41.13M	$48.08M
YoY Change	-50.19%	-24.9%	5.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$53.50M	$27.00K	$27.00K
YoY Change	198048.15%	-27.03%	-27.03%
Total Long-Term Liabilities	$53.50M	$27.00K	$27.00K
YoY Change	198048.15%	-27.03%	-27.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.48M	$41.13M	$48.08M
Total Long-Term Liabilities	$53.50M	$27.00K	$27.00K
Total Liabilities	$73.97M	$104.9M	$101.4M
YoY Change	-29.48%	-14.41%	9.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$177.8M	-$148.7M	-$147.1M
YoY Change	19.55%	15.25%	22.24%
Common Stock	$228.8M	$191.3M	$190.0M
YoY Change	19.62%	3.01%	39.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$49.81M	$30.16M	$39.94M
YoY Change
Total Liabilities & Shareholders Equity	$123.8M	$143.2M	$141.3M
YoY Change	-13.55%	-17.35%	36.07%

Cashflow Statement

Concept	2020 Q1	2019 Q1	2018 Q4
OPERATING ACTIVITIES
Net Income	-$3.600M	-$10.35M	-$11.68M
YoY Change	-65.21%	18.75%	-255.94%
Depreciation, Depletion And Amortization	$339.0K	$166.0K	$160.0K
YoY Change	104.22%	23.88%	60.0%
Cash From Operating Activities	-$15.13M	-$15.11M	-$9.060M
YoY Change	0.15%	-148.21%	92.77%
INVESTING ACTIVITIES
Capital Expenditures	$1.927M	$121.0K	-$570.0K
YoY Change	1492.56%	-70.77%	-29.63%
Acquisitions
YoY Change
Other Investing Activities	$2.340M	-$5.200M	-$4.650M
YoY Change	-145.0%	-34.01%	-89.42%
Cash From Investing Activities	$414.0K	-$5.316M	-$5.220M
YoY Change	-107.79%	-35.9%	-88.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	$0.00	10.00K
YoY Change		-100.0%	-98.33%
NET CHANGE
Cash From Operating Activities	-$15.13M	-$15.11M	-9.060M
Cash From Investing Activities	$414.0K	-$5.316M	-5.220M
Cash From Financing Activities	$0.00	$0.00	10.00K
Net Change In Cash	-$14.83M	-$22.77M	-14.27M
YoY Change	-34.88%	-131.79%	-70.79%
FREE CASH FLOW
Cash From Operating Activities	-$15.13M	-$15.11M	-$9.060M
Capital Expenditures	$1.927M	$121.0K	-$570.0K
Free Cash Flow	-$17.06M	-$15.23M	-$8.490M
YoY Change	12.01%	-149.24%	118.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55212437	shares
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q2	dei	Entity Public Float EntityPublicFloat	206297429	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Trading Symbol TradingSymbol	PIRS
CY2018	pirs	Accretionof Convertible Preferred Stock AccretionofConvertiblePreferredStock	0	USD
CY2019	pirs	Accretionof Convertible Preferred Stock AccretionofConvertiblePreferredStock	2830	USD
CY2018Q4	pirs	Accrued License Obligations AccruedLicenseObligations	2523000	USD
CY2019Q4	pirs	Accrued License Obligations AccruedLicenseObligations	62000	USD
CY2018Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1945000	USD
CY2019Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1048000	USD
CY2018Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	378000	USD
CY2019Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	522000	USD
CY2019	pirs	Additionsto Contractwith Customer Liability AdditionstoContractwithCustomerLiability	0	USD
CY2019Q4	pirs	Cash Cash Equivalents And Investments CashCashEquivalentsAndInvestments	104200000	USD
CY2018Q4	pirs	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	0	USD
CY2019Q4	pirs	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	4378000	USD
CY2018Q4	pirs	Deferred Tax Assets Accrued Compensation And Other DeferredTaxAssetsAccruedCompensationAndOther	304000	USD
CY2019Q4	pirs	Deferred Tax Assets Accrued Compensation And Other DeferredTaxAssetsAccruedCompensationAndOther	328000	USD
CY2018Q4	pirs	Deferred Tax Assets Depreciationand Other DeferredTaxAssetsDepreciationandOther	125000	USD
CY2019Q4	pirs	Deferred Tax Assets Depreciationand Other DeferredTaxAssetsDepreciationandOther	53000	USD
CY2018Q4	pirs	Deferred Tax Liabilities Lease Rightof Use Asset DeferredTaxLiabilitiesLeaseRightofUseAsset	0	USD
CY2019Q4	pirs	Deferred Tax Liabilities Lease Rightof Use Asset DeferredTaxLiabilitiesLeaseRightofUseAsset	4043000	USD
CY2018	pirs	Effective Income Tax Rate Reconciliation Rate Change Dueto Trade Taxon Net Operating Loss Percent EffectiveIncomeTaxRateReconciliationRateChangeDuetoTradeTaxonNetOperatingLossPercent	0.000
CY2019	pirs	Effective Income Tax Rate Reconciliation Rate Change Dueto Trade Taxon Net Operating Loss Percent EffectiveIncomeTaxRateReconciliationRateChangeDuetoTradeTaxonNetOperatingLossPercent	-0.064
CY2018	pirs	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	0	USD
CY2019	pirs	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	-794000	USD
CY2019Q4	pirs	Investments Fair Valuebelow Carrying Valueorinan Unrealized Loss Position InvestmentsFairValuebelowCarryingValueorinanUnrealizedLossPosition	0	USD
CY2018	pirs	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	0	USD
CY2019	pirs	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	408000	USD
CY2018	pirs	Proceeds From Issuance Of Common And Preferred Stock ProceedsFromIssuanceOfCommonAndPreferredStock	47211000	USD
CY2019	pirs	Proceeds From Issuance Of Common And Preferred Stock ProceedsFromIssuanceOfCommonAndPreferredStock	30998000	USD
CY2018	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	241000	USD
CY2019	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	1235000	USD
CY2018	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	1762000	USD
CY2019	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	2633000	USD
CY2018	pirs	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	0	USD
CY2019	pirs	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	0	USD
CY2016Q2	pirs	Warrant Exercisable Period WarrantExercisablePeriod	P5Y
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9944000	USD
CY2018Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9114000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3350000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5374000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4943000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5803000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2701000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6787000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9114000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9944000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	943000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4251000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3366000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3567000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2982000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1995000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	189929000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	227468000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4943000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5374000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14700000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33400000	shares
CY2018Q4	us-gaap	Asset Backed Securities At Carrying Value AssetBackedSecuritiesAtCarryingValue	5758000	USD
CY2019Q4	us-gaap	Asset Backed Securities At Carrying Value AssetBackedSecuritiesAtCarryingValue	7950000	USD
CY2018Q4	us-gaap	Assets Assets	141341000	USD
CY2019Q4	us-gaap	Assets Assets	141097000	USD
CY2019Q1	us-gaap	Assets Assets	143177000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	135382000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	115013000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	53379000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	41964000	USD
CY2018Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	53240000	USD
CY2019Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	41894000	USD
CY2018Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
CY2019Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	57000	USD
CY2018Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	143000	USD
CY2019Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	127000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74867000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62260000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37878000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74867000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62260000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	36989000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12607000	USD
CY2018Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	71941000	USD
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55212437	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54151219	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55212437	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	54000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	55000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25041000	USD
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	89278000	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	156888	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	123238	shares
CY2018Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	10910000	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54151219	shares
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24482000	USD
CY2017Q2	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	1100000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	300000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	35612000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11256000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	53303000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	47258000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	56780000	USD
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	32200000	USD
CY2019Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-1641000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-148000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-148000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-164000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-164000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	492000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4043000	USD
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3374000	USD
CY2019Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1005000	USD
CY2018Q4	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	35000	USD
CY2019Q1	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	641000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31308000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38009000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27879000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30455000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2359000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2705000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	90000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30816000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33966000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	98000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	394000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0	USD
CY2018	us-gaap	Depreciation Depreciation	600000	USD
CY2018	us-gaap	Depreciation Depreciation	570000	USD
CY2019	us-gaap	Depreciation Depreciation	600000	USD
CY2019	us-gaap	Depreciation Depreciation	632000	USD
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1581000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2144000	USD
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.012
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.231
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.152
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.074
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.019
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.008
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.010
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.020
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.025
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.005
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.008
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	-0.081
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	-0.012
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.007
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2380000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2870000	USD
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9300000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M15D
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-22000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	61000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18442000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18440000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-10633000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12063000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27066000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25469000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-16433000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13406000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-27066000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-25469000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-312000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	908000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	764000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1257000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12511000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4055000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3249000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-914000	USD
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9308000	USD
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-28524000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3939000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	679000	USD
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1962000	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1714000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	500000	USD
CY2019Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	11500000	USD
CY2019	us-gaap	Lease Cost LeaseCost	1817000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	28202000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	16790000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2317000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2214000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2214000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2249000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2418000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11985000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12Y6M
CY2018Q4	us-gaap	Liabilities Liabilities	101406000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	89745000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	104883000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141341000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141097000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	143177000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48076000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27003000	USD
CY2018	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	1651000	USD
CY2019	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	1161000	USD
CY2018Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	7791000	USD
CY2019Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	47384000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48511000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32166000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8875000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9838000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1066000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52467000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-26754000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-25469000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26754000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28299000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	59932000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	73436000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-30831000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-27157000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1524000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	16217000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	733000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	442000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15484000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	461000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	500000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3436000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	868000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y1M6D
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	945000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	458000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	910000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3146000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2030000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1196000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	973000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	517000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	14000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1196000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4072000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5290000	USD
CY2019Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50000000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	88358000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	63325000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	973000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	164000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2018	us-gaap	Other Income OtherIncome	91000	USD
CY2019	us-gaap	Other Income OtherIncome	0	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-75000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	69000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1803000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	117582000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	59317000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1698000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2462000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4963	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2907	shares
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4574000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	22047000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	8292000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	986000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	600000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	553000	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	369000	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	314000	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	300000	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	246000	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	200000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8415000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23069000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5049000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19502000	USD
CY2018	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	1000000	USD
CY2019	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	300000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41490000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	38294000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54996000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147066000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-174176000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148707000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27248000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	43646000	USD
CY2018	us-gaap	Revenues Revenues	29101000	USD
CY2019	us-gaap	Revenues Revenues	46279000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	4943000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	5374000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	53240000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	41894000	USD
CY2016Q2	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	1	shares
CY2019	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	113112	shares
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	596269	shares
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	279075	shares
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	314000	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	246000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	369000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	47211000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30998000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	986000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	553000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	11522000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	39935000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	51352000	USD
CY2018Q4	us-gaap	Trading Securities TradingSecurities	39964000	USD
CY2019Q4	us-gaap	Trading Securities TradingSecurities	28644000	USD
CY2018Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	7518000	USD
CY2019Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	5300000	USD
CY2018	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	681000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	14000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6157000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6032000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	125000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-3200000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	293000	USD
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53081000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50625000	shares
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk and Off-Balance Sheet Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no financial instruments with off‑balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments, and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001583648-20-000015-index-headers.html	Edgar Link	pending
0001583648-20-000015-index.html	Edgar Link	pending
0001583648-20-000015.txt	Edgar Link	pending
0001583648-20-000015-xbrl.zip	Edgar Link	pending
a344charta01.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g325265g27p10.jpg	Edgar Link	pending
g325265g32v61.jpg	Edgar Link	pending
g325265g36v14.jpg	Edgar Link	pending
g325265g37k28.jpg	Edgar Link	pending
g325265g58h49.jpg	Edgar Link	pending
g325265g72q73.jpg	Edgar Link	pending
g325265g74z83.jpg	Edgar Link	pending
pirs-20191231.xml	Edgar Link	completed
pirs-20191231.xsd	Edgar Link	pending
pirs-20191231_cal.xml	Edgar Link	unprocessable
pirs-20191231_def.xml	Edgar Link	unprocessable
pirs-20191231_lab.xml	Edgar Link	unprocessable
pirs-20191231_pre.xml	Edgar Link	unprocessable
pirs12-31x201910xk.htm	Edgar Link	pending
pirs12-31x2019ex211.htm	Edgar Link	pending
pirs12-31x2019ex231.htm	Edgar Link	pending
pirs12-31x2019ex311.htm	Edgar Link	pending
pirs12-31x2019ex312.htm	Edgar Link	pending
pirs12-31x2019ex321.htm	Edgar Link	pending
pirs12-31x2019ex322.htm	Edgar Link	pending
pirs12312019ex-43.htm	Edgar Link	pending
pirs12312019ex-43001.jpg	Edgar Link	pending
pirs12312019ex-43002.jpg	Edgar Link	pending
pirs12312019ex-43003.jpg	Edgar Link	pending
pirs12312019ex1016.htm	Edgar Link	pending
pirs12312019ex1016001.jpg	Edgar Link	pending
pirs12312019ex1016002.jpg	Edgar Link	pending
pirs12312019ex1016003.jpg	Edgar Link	pending
pirs12312019ex1016004.jpg	Edgar Link	pending
pirs12312019ex1016005.jpg	Edgar Link	pending
pirs12312019ex1016006.jpg	Edgar Link	pending
pirs12312019ex1016007.jpg	Edgar Link	pending
pirs12312019ex1025.htm	Edgar Link	pending
pirs12312019ex1025001.jpg	Edgar Link	pending
pirs12312019ex1025002.jpg	Edgar Link	pending
pirs12312019ex1025003.jpg	Edgar Link	pending
pirs12312019ex1025004.jpg	Edgar Link	pending
pirs12312019ex1025005.jpg	Edgar Link	pending
pirs12312019ex1025006.jpg	Edgar Link	pending
pirs12312019ex1025007.jpg	Edgar Link	pending
pirs12312019ex1025008.jpg	Edgar Link	pending
pirs12312019ex1025009.jpg	Edgar Link	pending
pirs12312019ex1025010.jpg	Edgar Link	pending
pirs12312019ex1025011.jpg	Edgar Link	pending
pirs12312019ex1025012.jpg	Edgar Link	pending
pirs12312019ex1026.htm	Edgar Link	pending
pirs12312019ex1026001.jpg	Edgar Link	pending
pirs12312019ex1026002.jpg	Edgar Link	pending
pirs12312019ex1026003.jpg	Edgar Link	pending
pirs12312019ex1026004.jpg	Edgar Link	pending
pirs12312019ex141.htm	Edgar Link	pending
pirs12312019ex141001.jpg	Edgar Link	pending
pirs12312019ex141002.jpg	Edgar Link	pending
pirs12312019ex141003.jpg	Edgar Link	pending
pirs12312019ex141004.jpg	Edgar Link	pending
pirs12312019ex141005.jpg	Edgar Link	pending
pirs12312019ex141006.jpg	Edgar Link	pending
pirs12312019ex141007.jpg	Edgar Link	pending
pirs12312019ex141008.jpg	Edgar Link	pending
pirs12312019ex141009.jpg	Edgar Link	pending
pirs12312019ex141010.jpg	Edgar Link	pending
pirs12312019ex141011.jpg	Edgar Link	pending
pirs12312019ex141012.jpg	Edgar Link	pending
pirs12312019ex141013.jpg	Edgar Link	pending
pirs12312019ex141014.jpg	Edgar Link	pending
pirs12312019ex141015.jpg	Edgar Link	pending
pirs12312019ex141016.jpg	Edgar Link	pending
pirs12312019ex141017.jpg	Edgar Link	pending
pirs12312019ex141018.jpg	Edgar Link	pending
pirs12312019ex141019.jpg	Edgar Link	pending
pirs12312019ex141020.jpg	Edgar Link	pending
pirs12312019ex141021.jpg	Edgar Link	pending
pirs12312019ex141022.jpg	Edgar Link	pending
pirs12312019exh1031.htm	Edgar Link	pending
pirs12312019exh1031001.jpg	Edgar Link	pending
pirs12312019exh1031002.jpg	Edgar Link	pending
pirs12312019exh1031003.jpg	Edgar Link	pending
pirs12312019exh1031004.jpg	Edgar Link	pending
pirs12312019exh1031005.jpg	Edgar Link	pending
pirs12312019exh1032.htm	Edgar Link	pending
pirs12312019exh1032001.jpg	Edgar Link	pending
pirs12312019exh1032002.jpg	Edgar Link	pending
pirs12312019exh1032003.jpg	Edgar Link	pending
pirs12312019exh1032004.jpg	Edgar Link	pending
pirs12312019exh1032005.jpg	Edgar Link	pending
pirs12312019exh1032006.jpg	Edgar Link	pending
pirs12312019exh1032007.jpg	Edgar Link	pending
programpipeline.jpg	Edgar Link	pending
prs06010kfigurea01.jpg	Edgar Link	pending
prs060a10.jpg	Edgar Link	pending
prs3432a03.jpg	Edgar Link	pending
prs343a03.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
Pieris Pharmaceuticals Inc Stock $pirs

2020 Q1 Form 10-K Financial Statement

#000158364820000015 Filed on March 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS Pieris Pharmaceuticals Inc Stock $pirs

2020 Q1 Form 10-K Financial Statement

#000158364820000015 Filed on March 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
Pieris Pharmaceuticals Inc Stock $pirs